Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for human papillomavirus-related squamous cell carcinoma has been reported in the published literature.
11 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE3, 6 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04900623](https://clinicaltrials.gov/study/NCT04900623) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:36 PM UTC
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study |
PHASE2 |
Jonathan Schoenfeld, MD, MPH |
RECRUITING |
[NCT05639972](https://clinicaltrials.gov/study/NCT05639972) | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | PHASE1 | Christian Hinrichs | RECRUITING |
[NCT05686226](https://clinicaltrials.gov/study/NCT05686226) | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | PHASE2 | Christian Hinrichs | RECRUITING |
[NCT06949800](https://clinicaltrials.gov/study/NCT06949800) | CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial | PHASE2 | University of California, San Francisco | RECRUITING |
123 publications have been identified in PubMed for human papillomavirus-related squamous cell carcinoma. Research spans Review / Meta-Analysis (27%), Diagnostic / Biomarker (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 33 | 27% |
Testing and diagnosis research | 22 | 18% |
Disease patterns and progression | 22 | 18% |
Laboratory research | 21 | 17% |
Clinical study results | 15 | 12% |
Patient case studies | 8 | 7% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Sali AP (2026). [PMID: 41540754](https://pubmed.ncbi.nlm.nih.gov/41540754/). *Adv Anat Pathol*. [Review / Meta-Analysis]
Lipner SR (2026). [PMID: 42105921](https://pubmed.ncbi.nlm.nih.gov/42105921/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Li R (2026). [PMID: 41074580](https://pubmed.ncbi.nlm.nih.gov/41074580/). *Int J Cancer*. [Basic Science / Preclinical]
Bulfoni M (2026). [PMID: 40762035](https://pubmed.ncbi.nlm.nih.gov/40762035/). *Head Neck*. [Diagnostic / Biomarker]
Schouten CS (2026). [PMID: 41236143](https://pubmed.ncbi.nlm.nih.gov/41236143/). *J Oral Pathol Med*. [Diagnostic / Biomarker]
Prasad M (2026). [PMID: 41603724](https://pubmed.ncbi.nlm.nih.gov/41603724/). *Clin Cancer Res*. [Basic Science / Preclinical]
Baliton M (2026). [PMID: 42042797](https://pubmed.ncbi.nlm.nih.gov/42042797/). *Vaccines (Basel)*. [Review / Meta-Analysis]
Zhang H (2026). [PMID: 41859712](https://pubmed.ncbi.nlm.nih.gov/41859712/). *Int J Womens Health*. [Case Report / Case Series]
Vigna Taglianti R (2026). [PMID: 41970299](https://pubmed.ncbi.nlm.nih.gov/41970299/). *Clin Case Rep*. [Case Report / Case Series]
Steele K (2026). [PMID: 41621277](https://pubmed.ncbi.nlm.nih.gov/41621277/). *Oral Oncol*. [Review / Meta-Analysis]